CYP1A1 and CYP1B1 genes in race-related Prostate Cancer
种族相关前列腺癌中的 CYP1A1 和 CYP1B1 基因
基本信息
- 批准号:6666982
- 负责人:
- 金额:$ 26.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-09-05 至 2008-08-31
- 项目状态:已结题
- 来源:
- 关键词:African American clinical research cytochrome P450 enzyme activity genetic polymorphism genetic susceptibility human genetic material tag human tissue in situ hybridization male neoplasm /cancer genetics neoplasm /cancer relapse /recurrence prostate neoplasms racial /ethnic difference single nucleotide polymorphism site directed mutagenesis steroid hormone metabolism transfection
项目摘要
DESCRIPTION (provided by applicant): The main goal of this project is to investigate whether over-expression of cytochrome P450 1A1 (CYP1A1) and cytochrome P4501 B1 (CYP1B1) genes can be risk factors for race-related prostate cancer. Rationale is that African-Americans have twice the risk of Whites for presenting with advanced-stage prostate cancer. The mortality of African-American men 40-60 years of age due to prostate cancer is almost 2-3 folds greater than that of White men of the same age. The genetic basis for racial / ethnic differences in prostate cancer incidence is not known. To address this problem, we have targeted the CYP1A1 and CYP1 B1 genes because their products (2-OH-E2 and 4-OH-E2) are highly carcinogenic. This is a first step towards investigating the genetic basis for racial / ethnic differences in prostate cancer incidence. Based on our prior publications and preliminary data, we hypothesize that the CYP1A1 and CYP1 B1 genes are risk factors for race-related prostate cancer. Specific Aim # 1: To test the hypothesis that CYP1A1 and CYP1 B1 genes are hyper-activated during malignant transformation of race-related prostate cancer. Under this specific aim, we will analyze mRNA expression of the CYP1A1 and CYP1 B1 genes by real-time PCR in different stages and grades of race-related prostate cancer. In situ hybridization will be used to localize gene expression in prostate tissues. Enzyme activities of CYP1 A1 and CYP1 B1 will be analyzed in prostate tissues by radio-isotopic methods. Specific Aim # 2: To test the hypothesis that single nucleotide polymorphisms of CYP1A1 and CYP1 B1 genes are risk factors for prostate cancer. Under this specific aim, we will analyze single nucleotide polymorphisms of four polymorphic sites of the CYPIA1 gene and six polymorphic sites of the CYP1 B1 gene in different stages and grades of race-related prostate cancer. SNPs will be analyzed by PCR-RFLP (restriction fragment length polymorphism) and direct genomic sequencing. Specific Aim # 3: To test the hypothesis that transfection of polymorphic variants of CYP1A1 and CYP1 B1 in E.Coli can hyperactivate estrogen hydoxylase activities using site-directed mutagenesis assays. We will investigate whether polymorphic variants of CYP1 A1 and CYP1 B1 have higher estrogen hydroxylase activities as compared to wild-type. We will also investigate whether estrogen hydroxylase activities and estrogen metabolites (2-OHE2 and 4-OH-E2) are associated with prostate cancer recurrence.
描述(由申请人提供):该项目的主要目的是研究细胞色素P450 1A1 (CYP1A1)和细胞色素P4501 B1 (CYP1B1)基因的过表达是否可能是种族相关前列腺癌的危险因素。理由是非洲裔美国人患晚期前列腺癌的风险是白人的两倍。40-60岁非裔美国男性因前列腺癌的死亡率几乎是同年龄白人男性的2-3倍。前列腺癌发病率的种族/民族差异的遗传基础尚不清楚。为了解决这个问题,我们针对CYP1A1和cyp1b1基因,因为它们的产物(2-OH-E2和4-OH-E2)是高度致癌的。这是研究前列腺癌发病率的种族/民族差异的遗传基础的第一步。基于我们之前的出版物和初步数据,我们假设CYP1A1和cyp1b1基因是种族相关前列腺癌的危险因素。具体目的1:验证CYP1A1和cyp1b1基因在种族相关前列腺癌恶性转化过程中过度激活的假设。为此,我们将采用real-time PCR技术分析不同分期和分级的种族相关性前列腺癌患者CYP1A1和cyp1b1基因的mRNA表达情况。原位杂交将用于定位前列腺组织中的基因表达。用放射性同位素法分析前列腺组织中CYP1 A1和CYP1 B1的酶活性。具体目标# 2:验证CYP1A1和cyp1b1基因单核苷酸多态性是前列腺癌危险因素的假设。在这个特定的目的下,我们将分析CYPIA1基因的4个多态性位点和cyp1b1基因的6个多态性位点在不同阶段和等级的种族相关性前列腺癌中的单核苷酸多态性。snp将通过PCR-RFLP(限制性片段长度多态性)和直接基因组测序进行分析。特异性目的# 3:通过位点定向诱变试验验证转染大肠杆菌中CYP1A1和cyp1b1多态性变体可以过度激活雌激素羟化酶活性的假设。我们将研究CYP1 A1和CYP1 B1的多态性变异是否比野生型具有更高的雌激素羟化酶活性。我们还将研究雌激素羟化酶活性和雌激素代谢产物(2-OHE2和4-OH-E2)是否与前列腺癌复发有关。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RAJVIR DAHIYA其他文献
RAJVIR DAHIYA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RAJVIR DAHIYA', 18)}}的其他基金
Molecular biomarkers for kidney cancer prognosis using non-coding RNAs
使用非编码 RNA 进行肾癌预后的分子生物标志物
- 批准号:
9270533 - 财政年份:2016
- 资助金额:
$ 26.97万 - 项目类别:
Molecular biomarkers for kidney cancer prognosis using non-coding RNAs
使用非编码 RNA 进行肾癌预后的分子生物标志物
- 批准号:
9052372 - 财政年份:2016
- 资助金额:
$ 26.97万 - 项目类别:
Genetic factors for race related prostate cancer.
种族相关前列腺癌的遗传因素。
- 批准号:
9314426 - 财政年份:2015
- 资助金额:
$ 26.97万 - 项目类别:
Genetic factors for race related prostate cancer.
种族相关前列腺癌的遗传因素。
- 批准号:
8874808 - 财政年份:2015
- 资助金额:
$ 26.97万 - 项目类别:
Role of genetic biomarkers in clinical assessment of prostate cancer
遗传生物标志物在前列腺癌临床评估中的作用
- 批准号:
8246285 - 财政年份:2012
- 资助金额:
$ 26.97万 - 项目类别:
Role of genetic biomarkers in clinical assessment of prostate cancer
遗传生物标志物在前列腺癌临床评估中的作用
- 批准号:
8764702 - 财政年份:2012
- 资助金额:
$ 26.97万 - 项目类别:
Role of genetic biomarkers in clinical assessment of prostate cancer
遗传生物标志物在前列腺癌临床评估中的作用
- 批准号:
8598789 - 财政年份:2012
- 资助金额:
$ 26.97万 - 项目类别:
Chemo-dietary prevention, miRNAs, epigenetic and prostate cancer
化学饮食预防、miRNA、表观遗传和前列腺癌
- 批准号:
8149764 - 财政年份:2011
- 资助金额:
$ 26.97万 - 项目类别:
Chemo-dietary prevention, miRNAs, epigenetic and prostate cancer
化学饮食预防、miRNA、表观遗传和前列腺癌
- 批准号:
8658043 - 财政年份:2011
- 资助金额:
$ 26.97万 - 项目类别:
相似海外基金
FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
- 批准号:
EP/Y036395/1 - 财政年份:2024
- 资助金额:
$ 26.97万 - 项目类别:
Research Grant
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
- 批准号:
10764456 - 财政年份:2023
- 资助金额:
$ 26.97万 - 项目类别:
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
- 批准号:
10715568 - 财政年份:2023
- 资助金额:
$ 26.97万 - 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
- 批准号:
10743328 - 财政年份:2023
- 资助金额:
$ 26.97万 - 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
- 批准号:
10638813 - 财政年份:2023
- 资助金额:
$ 26.97万 - 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
- 批准号:
10823828 - 财政年份:2023
- 资助金额:
$ 26.97万 - 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
- 批准号:
10828665 - 财政年份:2023
- 资助金额:
$ 26.97万 - 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
- 批准号:
10721095 - 财政年份:2023
- 资助金额:
$ 26.97万 - 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
- 批准号:
10795328 - 财政年份:2023
- 资助金额:
$ 26.97万 - 项目类别:
Mentoring Scientists for Careers in HIV Translational Clinical Research
指导科学家从事艾滋病毒转化临床研究
- 批准号:
10762827 - 财政年份:2023
- 资助金额:
$ 26.97万 - 项目类别:














{{item.name}}会员




